Please ensure Javascript is enabled for purposes of website accessibility

Intercept Pharmaceuticals Shares Fall 13% After FDA Delays an Advisory Committee Meeting

By Brian Orelli, PhD – May 22, 2020 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are feeling more uncertainty about whether obeticholic acid will be approved as a treatment for liver fibrosis due to nonalcoholic steatohepatitis.

Shares of Intercept Pharmaceuticals (ICPT -0.21%) were down 13% at 3 p.m. EDT on Friday after the company disclosed that the Food and Drug Administration plans to postpone an advisory committee meeting to review obeticholic acid as a treatment for liver fibrosis due to nonalcoholic steatohepatitis (NASH).

The meeting had been tentatively scheduled for June 9, but Intercept plans to submit additional data requested by the FDA within the next week, so the agency wants to push back the meeting to give itself time to review the additional data. The delay will likely cause the FDA to miss the agency's June 26 goal for completing its review of the marketing application.

By itself, the delayed approval, which shouldn't last more than a couple of months, doesn't justify a 13.6% decline in Intercept's valuation. But biotech investors are rightfully discounting the company's shares because the FDA requested additional data, which suggests that an approval isn't a slam dunk.

Expect delays roadsign

Image source: Getty Images.

Obeticholic acid is already approved as a treatment for primary biliary cholangitis (PBC) under the brand name Ocaliva, so the FDA's decision to convene a meeting of outside experts may seem a little weird. The agency typically holds advisory committee meetings for new drugs with new mechanisms of action.

But, in this case, the need for an advisory committee meeting is about the disease, NASH, which doesn't have any approved drugs to treat it. Over the years, the FDA's views have evolved on the matter of the correct way to measure the effectiveness of drugs against NASH, which is a slow-developing disease.

An approval for Ocaliva as a NASH treatment would help Intercept grow revenue substantially given that NASH is a much larger market than PBC, which contributed $72.7 million in sales in the first quarter.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$14.06 (-0.21%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.